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ABSTRACT 
The objectives of the research are to test the hypothesis that pelvic outlet 
diameter (POD) is associated with pelvic organ prolapse (POP) in squirrel monkeys, and 
to measure long-term satisfaction of women treated with sacral neuromodulation 
(InterStim®) for refractory urinary urge incontinence, urinary urgency, and frequency.  
Magnetic resonance images (MRI) were obtained from 55 females with and without 
POP. Associations of age, parity, and body weight to POD were evaluated with linear 
regression analysis, while relationships between age, parity, and POD with POP were 
examined with multiple regression analysis.  Women who were at least 3.3 years remote 
from InterStim® implantation were contacted by telephone to assess treatment 
satisfaction (Likert-type scale), symptom severity (UDI-6), disease related quality of life 
(IIQ-7), and patient global impression of improvement (PGI).   
Pelvic outlet diameter was not related to parity (p = 0.10) or weight (p = 0.053), 
but was inversely related to age. (p = 0.011) Animals with POP did not differ from those 
without POP in age (p = 0.10), weight (p = 0.17), or POD (p = 0.99). The groups 
differed in parity (p = 0.007) and multiple regression methods demonstrated that only 
parity had a significant relationship with POP (p = 0.002).  In measuring long-term 
satisfaction of those treated with sacral neuromodulation, 37.5% of respondents were 
“satisfied” with their InterStim® and 50% would have the procedure again. Satisfied 
subjects were found to be younger then dissatisfied subjects (p = 0.10), and reported a 
median improvement in their bladder symptoms of 50%.  Objective incontinence 
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parameters and survey scores performed preoperatively and improvement during test 
stimulation were not predictive of long-term patient satisfaction.  In conclusion, POD 
size does not contribute to POP in squirrel monkeys.  Of the 24 subjects who were 
available for follow-up after 51 months of treatment, 50% would have InterStim® again. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
Pelvic floor disorders consist of urinary incontinence, fecal incontinence, and pelvic 
organ prolapse.   A recent series of cross-sectional national health surveys estimates that 
25% of adult U.S. women suffer from at least one pelvic floor disorder (1).  By subtype, 
this includes 17% of women with urinary incontinence, 9.4% of women with fecal 
incontinence, and 2.9% of women with symptomatic pelvic organ prolapse.  In addition, 
the proportion of women experiencing at least one pelvic floor disorder increases with 
age from 9.7% of women ages 20 to 39 to 36.8% of women ages 60-79, and 49.7% of 
women over the age of 80 (2).  Pelvic floor disorders clearly pose a public health 
challenge as census data predicts a demographic increase in the number of elderly 
women (3).   
I.1  Pelvic Organ Prolapse 
In order to meet the future clinical demands of preventing, diagnosing and 
treating pelvic floor disorders, medical research will have to build upon what is known 
about the etiology and in particular risk factors and pathophysiology.  The etiology of 
pelvic organ prolapse is multifactorial and includes advancing age, parity (in particular 
vaginal childbirth), obesity, previous surgery (hysterectomy, Burch colposuspension), 
and genetic factors (4-7).  These risk factors have also been described as predisposing, 
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inciting, promoting, and decompensating (7).  Established risk factors include increasing 
age, higher gravity and parity (in particular vaginal births) and obesity (5, 6).  Potential 
risk factors are more diverse and include a multitude of factors such as obstetrical 
history (regardless of route of delivery), pervious hysterectomy (especially if indication 
was for prolapse) smoking, ethnicity, and shape or orientation of the bony pelvis.     
The relationship between the bony pelvis and pelvic floor disorders has been 
studied in humans to various degrees (8, 9).   For example, a case-controlled study of 
women who underwent magnetic resonance imaging (MRI) of the pelvis found that a 
wide transverse inlet and narrow obstetrical conjugate were associated with pelvic floor 
disorders, duplicating results seen in a control group of women who underwent 
computed tomography.   The authors then concluded that these particular pelvic 
dimensions (wide transverse inlet and narrow obstetrical conjugate) predispose women 
to traumatic childbirth and subsequent development of pelvic floor neuromuscular 
changes that results in pelvic organ prolapse.    
The authors of the first study utilize the squirrel monkey as an experimental 
model in order to expand previous research associating bony pelvis dimensions and the 
development of pelvic organ prolapse.  The squirrel monkey shares several 
characteristics with humans that make them useful for studying pelvic organ prolapse 
(10, 11).  For example, fifty percent of older female squirrel monkeys demonstrate 
pelvic support defects (10), and like humans, these pelvic support defects are associated 
with childbirth and aging (11).  Because squirrel monkeys deliver large infants (14% of 
maternal body weight) relative to maternal size, they are susceptible to pelvic floor 
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injury secondary to labor dystocia, just like their human counterparts.  By using a cohort 
of female squirrel monkeys with known obstetrical histories across various ages the 
authors assess the association between pelvic outlet diameter and	pelvic organ prolapse 
in the squirrel monkey.  Conclusions from this study will further characterize the squirrel 
monkey as an animal model for studying human pelvic organ prolapse. 
 
I.2  Urinary Incontinence and Overactive Bladder 
 
Urinary incontinence is defined as “the complaint of any involuntary leakage of 
urine” (12).  It is classified by the symptoms or events that occur during the leakage.  
Two prominent classifications of urinary incontinence are stress urinary incontinence, 
which is the “complaint of involuntary loss of urine on effort or physical exertion (e.g. 
sporting activities) or on sneezing or coughing, and urgency (urinary) incontinence, 
which refers to a “complaint of involuntary loss of urine associated with urgency”.   
Urinary incontinence constitutes a significant health problem in women, as a cross-
sectional analysis of non-pregnant women determined approximately 15.7% of women 
experienced moderate or severe urinary incontinence (2).  Prevalence rates will depend 
on the severity of leakage, with higher reported rates representing mild disease and 
lower rates representing more severe variants.   
Like pelvic organ prolapse, urinary incontinence is more prevalent in the female 
gender and advancing age.  The relationship between age and urinary incontinence is not 
linear, but rather bimodal, with the first peak onset occurring between ages 40-60, with 
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the second prevalence increase occurring after age 65 (13).  The effect of childbirth on 
the prevalence of urinary incontinence has been demonstrated in young and middle age 
women (< age 50) but less so in older women (14).  A cross-sectional study of 
Norwegian women demonstrated that the effect of 2 or more deliveries on urinary 
incontinence was greatest in younger women aged (ages 20-34 years) (15).  
Interestingly, this effect of childbirth was decreased among women ages 35-64, and not 
associated with urinary incontinence in women older then 65 (15). 
 Overactive bladder (OAB) is considered to be a clinical diagnosis defined as   
“urinary urgency, usually accompanied by frequency and nocturia (waking up from 
sleep in order to urinate), with or without urgency urinary incontinence, in the absence 
of urinary tract infection or other obvious pathology (12, 16).  The overall prevalence in 
the United States among females, according to a national telephone survey using 
clinically-validated questionnaires of non-institutionalized adults and was representative 
of the population in terms of sex, age, and geographical region, is 16.9% (17).    The 
prevalence also increases with age from 2.0% to 19% with a significant increase after 44 
years.  Total costs of OAB in the USA was estimated to be $65.9 billion in 2007, 22.1 % 
of which was accounted for by indirect costs (18).  
 For patients who have failed first (behavioral therapy) and second line treatments 
(pharmacologic management) for overactive bladder and urinary urge incontinence, 
neuromodulation, in particular sacral nerve stimulation (SNS), may be offered to 
carefully selected patients (16).  Sacral nerve stimulation is an FDA-approved treatment 
for overactive bladder and urinary incontinence that has demonstrated the ability to 
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significantly improve patient quality of life and urinary symptoms as measured by both 
subjective and objective criteria.  It involves stimulation of the pelvic plexus and 
pudendal nerves that innervate the bladder, pelvic floor muscles and rectum (14), and 
has been available in the United States since 1997 and in Europe since 1994 (19).  
Current FDA-approved indications for SNS include urinary urge incontinence, urgency-
frequency, non-obstructive urinary retention, and most recently (2011), fecal 
incontinence. 
The sacral neuromodulation procedure known as InterStim® (Medtronic, Inc., 
Minneapolis, MN) is performed in two stages (14, 19), both of which are performed in 
an outpatient surgery setting.  Stage 1 involves placing a permanent quadipolar lead wire 
adjacent to a sacral root (typically S3), under fluoroscopic guidance.  The patient then 
undergoes a test phase for 7-14 days.  This period is essentially a clinical trial where the 
patient will monitor his or her urinary symptoms.  If he or she demonstrates greater then 
50% level of improvement in their symptoms by either subjective and/or objective 
parameters, they will then proceed to the Stage II procedure.  The Stage II procedure 
involves the implantation of a subcutaneous pulse generator (figures 7, 8, 9, 10).     
Literature reporting clinical outcomes for the treatment of urinary incontinence, 
overactive bladder, and other pelvic floor disorders may use any one or a combination of 
domains including the subject’s own assessment of their symptoms, an objective 
quantification of symptoms, findings from a clinician’s observations or exam, the 
patient’s perceived quality of life, and any socioeconomic measures(14).  A prospective 
analysis of patients who underwent SNS for the treatment of urgency (urinary) 
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incontinence showed a significant improvement in quality of life up to 36 months 
following implantation (20).  Van Kerrebroeck et al (21) used data from patient voiding 
diaries to determine long-term outcomes from a 5 –year multicenter prospective trial.  
Clinical success was defined as 50% greater improvement from baseline in voiding diary 
variables.  Their analysis revealed 68% of patients with urge incontinence, 56% with 
urgency frequency and 71% with retention had successful outcomes 5 years following 
implantation of the pulse generator. However, the authors did not report outcomes 
pertaining to patient satisfaction, perceived quality of life, or subjective assessment of 
symptoms.  
The authors of the second study seek to determine the long-term effect of sacral 
neuromodulation on disease specific quality of life and long-term satisfaction in subjects 
with urinary urge incontinence, urinary urgency, and frequency.  Subject demographics, 
comorbidities, and incontinence parameters (subjective and objective) were then 
analyzed for potential associations with improved or worsened outcomes.      
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CHAPTER II 
LACK OF ASSOCIATION OF PELVIC OUTLET DIAMETER WITH PELVIC 
ORGAN PROLAPSE IN SQUIRREL MONKEYS* 
II.1  Introduction
Historically, variations in size and shape of the human pelvis have generated 
1hypotheses for the etiology of pelvic floor disorders. The relationship between pelvic 
organ prolapse (POP) and bony pelvic architecture has been studied in humans to a 
limited degree (8, 9, 22).    
It is well accepted that animal research contributes to the study of human disease 
by allowing hypotheses to be tested in controlled settings that cannot be performed on 
humans. Squirrel monkeys have unique characteristics that make them useful for pelvic 
floor research.  For example, 50% of older females demonstrate pelvic support defects 
(10). As in humans, these pelvic support defects are associated with childbirth and aging 
(11). Since squirrel monkeys deliver large infants (14% of maternal body weight) 
relative to maternal size, they are susceptible to pelvic floor injury secondary to labor 
dystocia. Also, their lifespan is shorter than humans (2 versus 8 decades), which allows 
*Reprinted with kind permission from “Lack of Association of Pelvic Outlet Diameter 
with Pelvic Organ Prolapse in Squirrel Monkeys” Joyce JS, Dornak S, Gendron JM, 
Reyes M, Ruiz JC, Kuehl TJ, 2014.  International Urogynecology Journal, Volume 25, 
1121-6, Copyright 2014 by Springer. 
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for serial observation in a research setting. Because of these characteristics, research on 
squirrel monkey pelvic anatomy contributes to our knowledge-base of POP.     
Various modalities for imaging have been used to describe squirrel monkey 
pelvic anatomy.  In 1983, Aksel and Abee (23) used radiographic pelvimetry to evaluate 
the bony pelvic architecture in females with a focus on predicting the risk of stillbirth in 
captive breeding programs.  Later we used CT imaging to create 3-dimensional models 
of the bony pelvis of a small series (N = 9) of older animals without detailed obstetric 
histories (24). In both studies, of the five pelvic dimensions examined as illustrated in 
Figure 1, only the pelvic outlet diameter was related to stillbirth (23) and prolapse (24).  
Recently, magnetic resonance imaging (MRI) has been used to compare levator 
ani muscle volumes in monkeys with and without prolapse (25), and to compare the 
effects of delivery (26) and nerve injury (27) on pelvic floor musculature. However, 
these three articles did not address risk of prolapse in relationship to boney pelvis 
dimensions. Therefore, despite this research on muscle dimensions and contrast changes, 
the relationship between pelvic outlet diameter and prolapse in squirrel monkeys has 
been supported with only the limited observations using CT imaging. Therefore, we 
undertook this study to use a larger cohort of female squirrel monkeys with known 
obstetrical histories representing various ages to assess the association between pelvic 
outlet diameter and POP in the female squirrel monkey. 
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Figure 1. Lateral view (A) of a 3-dimensional reconstruction of the bony pelvis of an 
adult female squirrel monkey rotated 18 degrees about the spine with measured inlet and 
mid-pelvis diameters. Anteroposterior view (B) with measured inlet, mid-pelvis, and 
outlet diameters.   
II.2  Methods
Animals. A colony of squirrel monkeys housed at Scott and White Healthcare 
was used for this study. The use of these animals and MRI methodology was reviewed 
and approved by the Scott and White Institutional Animal Care and Use Committee. 
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Nineteen female parous squirrel monkeys with pelvic floor defects based on visual 
perineal evaluations using methods originally describe by Coates et al. (10) and/or the 
measured descent of the bladder base to greater than 7 mm below boney pelvic 
landmarks as defined and illustrated by Pierce et al. (27) were included along with 36 
adult females with normal pelvic floor support by both criteria. Animals were of a range 
of ages, parities, and weights. All animals in the study were initially obtained from the 
National Squirrel Monkey Breeding and Research Resource now located at the Michale 
E Keeling Center for Comparative Medicine and Research of The University of Texas 
MD Anderson Cancer Center in Bastrop, Texas.  
Imaging methods. MRI of the pelvic floor was performed on all female monkeys 
using a previously described technique (25-27).  Briefly, animals were sedated, given IV 
contrast (0.25 mmol/kg of gadolinium chelate as ProHance, Bracco Diagnostics, Inc. 
Princeton, NJ), and placed inside the MRI unit (3T Siemens Trios, Erlangen, Germany) 
with their back and legs supported in a natural position inside of an 8-channel wrist coil 
(model HRW, Philips Medical Systems, Waukesha, WI). Two localizing scans were 
obtained to set the region of interest for serial images from L7 through C4.  A sequence 
of echo gradient axial images was acquired during a 4.4-minute interval. Images were 
saved as a DICOM series and transferred to a work station with commercial software 
(3D-Doctor, Able Software Corp, Lexington, MA), which was used to review, 
manipulate, and measure the pelvic outlet diameter.  The pelvic outlet diameter, as 
originally defined by Aksel and Abee (23), is the distance between the inferior lateral 
margins of the obturator foramina at the level of the pubic arch (Figure 2). This is the 
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only measure of five previously related to development of prolapse (24).  Two 
independent reviewers (JSJ, TJK) performed all measurements in anteroposterior views. 
Bladder position change relative to a skeletal reference line was measured with a 
dynamic scan where abdominal pressure is applied using a neonatal blood pressure cuff 
placed around the animal’s abdomen using a previous described technique (26, 27). POP 
was also directly assessed by an established procedure using perineal visual examination 
(10).   
 
 
Figure 2.  MRI of female squirrel monkey pelvis at level of pelvic outlet diameter.  
Arrow demonstrates the measured pelvic outlet diameter.    
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Statistical analysis. Comparison of pelvic outlet diameter measurements by 2 
independent observers was made using Cronbach alpha for inter-rater correlation 
(MediCalc Software, Ostend, Belgium). Prolapse groupings were compared using 
Student’s t test for parametric variables. Linear regression analysis examined the 
relationship of the outlet dimension with age, parity, and weight. Multiple regression 
analysis examined the relationships of age, parity, and outlet dimension with the 
presence or absence of POP. These analyses were performed using Statistica software 
(StatSoft, Tulsa, OK). Receiver operative curve analysis was performed to establish a 
threshold criterion level for parity as predictor of development of POP (MediCalc 
Software, Ostend, Belgium). P values less than 0.05 were interpreted as significant. 
II.3  Results
The two observers independently performed measurements of 55 pelvic outlet 
diameters in 55 images independently. The measurements were highly correlated 
(Cronbach’s alpha = 0.96 with a lower 95% confidence limit of 0.94) which imply that 
there were no differences in measurements between the two observers (Figure 3). 
Therefore, the average values for the two observers were used for the remaining 
analyses.  
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Figure 3.  Inter-rater comparison for measurement of pelvic outlet diameter.  No 
difference between observers was found.   Linear regression with 95% confidence 
interval.  Crohnbach’s alpha = 0.96.  Lower 95% confidence interval of 0.94. 
 
Table 1 shows independent associations of parity, age, and weight with pelvic 
outlet diameter in the 55 subjects. The pelvic outlet diameter is not related to parity (p = 
0.10) or weight (p = 0.053), but is inversely related to age (p = 0.011).  Although weight 
has a tendency to be directly correlated to the outlet diameter, the effect is small (r2 = 
0.07). Figure 4 illustrates the inverse relationship of outlet diameter to age.   
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Table 1 Relationship between pelvic outlet diameter (POD) and parity, age, or weight 
Variable Correlation R2 p value* 
Parity -0.23 0.05 0.10 
Age -0.34 0.12 0.011 
Weight 0.26 0.07 0.053 
 
*Multiple regression model 
 
 
 
Figure 4.  Linear regression with 95% confidence interval comparing the pelvic outlet 
diameter of 55 animals to ages.  Outlet diameter was inversely associated with age. (p = 
0.011, r2 = 0.12). 
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Univariant analyses using Student’s t test demonstrate that animals with POP do 
not differ from those without POP in regard to age (p = 0.10), weight (p = 0.17), or 
pelvic outlet diameter (p = 0.99).  The two groups do differ in parity (p = 0.002 using 
Student’s t test). Using multiple regression, only parity demonstrated a significant 
relationship with POP (p = 0.007) (Table 2).  
 
Table 2 Factors related to pelvic organ prolapse in the squirrel monkey 
Factor Animals with 
POP (n =19) 
Animals without 
POP (n = 36) 
p level* p level** 
Parity 5.0 ± 2.4 2.3 ± 2.4 0.002 0.007 
Age (years) 12.0 ± 5.2 9.2 ± 6.3 0.10 0.99 
Body weight 
(g) 
750 ± 63 720 ± 84 0.17 0.08 
Outlet Diameter 
(mm) 
17.9 ± 1.2 17.9 ± 1.5 0.99 0.74 
 
*Univariate comparison using Student’s t tests 
**Multiple regression model 
 
Using Receiver-Operator Curve (ROC) methods, parity as a criterion had a 
significant (p < 0.0001) area under the curve (0.78 with 95% CI of .64 to .88) (Figure 5). 
The optimal criterion for parity as a threshold for prediction of POP was greater than 2 
vaginal deliveries (sensitivity of 64% and specificity of 89%); however, greater than 1 
vaginal delivery has a similar sensitivity (61%) and the same specificity (89%).   
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Figure 5. Receiver-operator curve with 95% confidence interval for analysis of the 
threshold number for parity in relation to pelvic organ prolapse in a cohort of 55 adult 
squirrel monkey females. Optimum criterion point (open circle) is for parity greater than 
2.  
 
II.4  Discussion 
 
As previous observations in squirrel monkeys supported the concept that of five 
boney pelvis measurements, only the pelvic outlet diameter in the anterioposterior 
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dimension can identify animals with a higher frequency of stillbirths (23) and POP (24), 
we anticipated that this trial would confirm the risk conferred by a smaller pelvic outlet 
for development of POP.  As illustrated in Figure 6, the fetal face is the presenting part 
as the majority of squirrel monkey deliveries are mentum anterior (28). However, in the 
current trial, only parity was related to the development of POP. Our study in squirrel 
monkeys showed that pelvic outlet diameters do not differ between animals with and 
without prolapse, which is consistent with the findings by Stein et al. (22). Stein et al. 
studied bony landmarks at the level of the pelvic floor in white women and found no 
association between outlet dimensions and POP (22).  
We also reaffirmed earlier observations that parity appears to be the most 
significant risk factor for prolapse development in squirrel monkeys (11).  However, in 
the previous study of a breeding colony, parity and age were highly associated, so that it 
was not possible to distinguish which of these characteristics might have the strongest 
effect. In our current study, age, weight, and outlet diameters were not associated with 
prolapse, suggesting that parity is the primary risk factor. In spite of a preliminary trial 
with a cohort of 9 older animals (24), the pelvic outlet diameter for animals with 
prolapse in the current study was the same as for animals without prolapse (17.9 ± 1.2 
and 17.9 ± 1.5 mm, respectively).  The measurements made by the two independent 
observers were precise and valid for this analysis.  
The inverse relationship between age and pelvic outlet diameter is unexplainable 
at this time.  It is possible that the older animals in this cohort had smaller pelvises to 
begin with, suggesting that the younger animals benefited from improved nutrition in 
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their captive environments. It is also possible that pelvises measurements might change 
with age. The later hypothesis is testable in the future by examining serial measurements 
in animals followed for an extended interval.  Although animal weight had a tendency to 
be correlated to outlet diameter, the effect was small.    
The advent of sensitive radiographic technology has enticed researchers to study 
bony pelvic architecture in humans in hopes of addressing various hypotheses pertaining 
to risk of development of pelvic organ prolapse. Using computed tomography, Sze et al. 
found that women with prolapse had larger transverse inlet diameters than women 
without prolapse (9).  Using MRI, Handa et al. found that a wider transverse inlet and a 
shorter obstetrical conjugate were significantly associated with pelvic floor disorders (8). 
In previous studies of five measures of the pelvic inlet and outlet in squirrel monkeys, 
only the pelvic outlet diameter was found to be related to stillbirth using radiographic 
projection (23) or POP using CT (24) in a small series of older animals. In squirrel 
monkeys, the ilium is longer and narrower and the outlet faces more dorsally (Figure 6). 
The fetal head does not simultaneously pass the sacral promontory and public 
symphysis, so some of the classically defined pelvic diameters may not be relevant to 
this species (29). There are no ischial spines as in the human pelvis. The fetal head does 
become bound circumferentially by maternal boney pelvis when it reaches the plane of 
the second sacral vertebra and the superior ramus of the pubic symphysis until it exits at 
the outlet position (29). The smallest of the measured diameters is the outlet (10, 24), so 
while this restriction would seem to be the most important, our study did not support this 
hypothesis.   
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Figure 6. Lateral radiograph of squirrel monkey fetus entering the birth canal (A), axial 
view of 3 dimensional reconstruction of CT scan with tail in front (B), and artist 
depiction of mentum anterior presentation (C) to demonstrate that anterioposterior outlet 
dimension represents a restriction for squirrel monkey vaginal delivery.  
It was the initial dilemma of impaired reproductive performance in captivity 
secondary to a high perinatal mortality rate that encouraged investigators to develop 
pelvimetry methods as a predictor of pregnancy outcome (23). This finding led to 
hypotheses associating traumatic pelvic floor injury from labor dystocia with subsequent 
prolapse.  Despite the suggested relationship between a small pelvic outlet diameter and 
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prolapse in an earlier and smaller cohort of squirrel monkeys (23), the currently study 
provides data from a different and larger cohort that does not support the earlier 
preliminary findings. Further investigation of pelvic organ prolapse etiology with a focus 
on the role of pregnancy and delivery in squirrel monkeys is warranted and in progress 
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CHAPTER III 
LONG-TERM ASSESSMENT OF PATIENT SATISFACTION AND QUALITY OF 
LIFE FOLLOWING SACRAL NEUROMODULATION FOR THE TREATMENT OF 
URINARY URGE INCONTINENCE, URGENCY AND FREQUENCY 
III.1  Introduction
Sacral neuromodulation (InterStim®, Medtronic, Inc., Minneapolis, MN) first 
received FDA approval for the treatment of urinary urge incontinence in 1997, then later 
received approval for the treatments of urinary urgency, frequency and non-obstructive 
urinary retention in 1999.   Since then, several studies have evaluated its long-term cure 
and efficacy rates.  A 5-year prospective multicenter trial evaluating long-term safety 
and efficacy in patients who received sacral neuromodulation for refractory urge 
incontinence, urgency frequency, and retention demonstrated 5-year post-implantation 
success rates of 68%, 56%, and 71% for urge incontinence, urgency frequency, and 
retention respectively (21).  In this study, the researchers defined clinical success as 
objective symptom improvement measured by voiding diaries.  Although they did 
attempt to address patient quality of life by using the Short Form-36 and Beck 
Depression Inventory, these instruments are more indicative of patient overall general 
health rather urinary incontinence or voiding dysfunction.    
In an effort to evaluate sacral neuromodulation’s effect on patient satisfaction 
and quality of life at least 1-year remote from InterStim® placement, Foster et al (30) 
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prospectively evaluated 52 patients with refractory urge incontinence with a satisfaction 
survey and the IIQ short form.  Investigators discovered that 84% of respondents were 
still satisfied with InterStim® treatment at an average interval of 27 months.  Satisfied 
subjects also demonstrated a significantly greater improvement with 24-hour pad 
weights during test stimulation than dissatisfied subjects, 85% versus 60% respectively.  
However, improvement in daily pad usage during test stimulation was not predictive of 
subject satisfaction. 
The purpose of this study is to measure long-term satisfaction of women treated 
with sacral neuromodulation for refractory urinary urge incontinence, urinary urgency, 
and frequency.  Subject demographics, comorbidities, objective incontinence 
parameters, and scores from symptom severity and disease related quality of life 
questionnaires were analyzed for potential associations with improved or worsened 
outcomes. 
      
III.2  Methods    
 
This was a prospective study approved by the University of Missouri Health 
Sciences institutional review board (IRB).  Subjects were included if they were 
implanted with InterStim® (Medtronic, Inc.) sacral neuromodulator for the treatment of 
urinary urge incontinence or urinary frequency and urgency between July 1, 2007 and 
August 30, 2010.  Subjects were excluded if they were non-English speaking or serving 
a prison sentence.  All subjects received their care from a single female pelvic medicine 
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and reconstructive surgery (FPMRS) physician at a large mid-western university 
hospital.   Subject demographics were collected from an IRB approved, continuous, 
prospective surgical database.   The subject’s medical history, physical examination, and 
scores from the Urogenital Distress Inventory-6 (UDI-6) and Incontinence Impact 
Questionnaire-7 (IIQ-7) validated questionnaires, recorded at the time of the initial 
evaluation for their urinary complaint, were collected from the subject’s electronic 
health record.  In addition, objective incontinence parameters (24-hr pad weight, daily 
pad usage [number of pads], and a 3-day bladder diary to document leakage episodes per 
day) recorded both before and during test stimulation, were collected from the patient’s 
electronic health record.   
All subjects underwent a test stimulation period of 6 to 8 days using the first 
stage lead placement (FSLP) with the tined lead technique.  The technique for FSLP and 
permanent device implantation has been previously described (31, 32).   
The subjects who proceeded to Stage II implantable pulse generator (IPG) placement 
were identified and contacted by either telephone or electronic mail for interview.  
Telephone contact attempts were made until the subject or caregiver answered the 
phone, or if the telephone company verified a non-working number.  A version of the 
interview was sent to the subject or her caregiver if that was her desired method of 
contact.  If the subject underwent lead placement revision or removal of IPG, the time 
interval between placement and revision/removal as well as its indication were recorded.  
The subject’s past medical history was then reviewed and updated to account for the 
acquisition/development of any acute or chronic medical illness.  
    24 
The primary outcome of the analysis was to measure long-term satisfaction, 
including perceived level of improvement, symptom severity and disease related quality 
of life in subjects who underwent sacral neuromodulation for the treatment of urinary 
urge incontinence, urinary urgency, and frequency.  Subject satisfaction was assessed by 
using a Likert-type scale and direct “yes” or “no” questions.  A Patient Global 
Impression of Improvement test was used to assess the subject’s perceived level of 
improvement of their urinary symptoms.  Symptom severity and disease related quality 
of life at the time of interview were assessed using the UDI-6 and IIQ-7 questionnaires.  
Subjects were also asked questions about daily pad usage, additional treatment sought 
for their urinary symptoms, and whether or not they would receive InterStim® treatment 
again in retrospect (Table 3).  Subjects were then queried on their last follow-up 
appointment for IPG assessment, their last evaluation for urinary tract infection, and 
whether or not they had symptoms of constipation (straining, hard stools, fewer then 1 
bowel movement a day).  Finally, dissatisfied subjects were asked why they believed 
their InterStim® was not producing satisfactory treatment results. 
The secondary outcome of the analysis was to identify any associations between 
preoperative variables (medical history, examination, UDI-6 and IIQ-7 scores, and the 
pretest and test phase objective incontinence parameters) and long-term subject 
satisfaction.  In addition, subject UDI-6 and IIQ-7 scores recorded at the time of 
interview, were compared to UDI-6 and IIQ-7 scores recorded at the time of the 
subject’s initial evaluation.   
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Table 3 Questions assessing patient satisfaction at time of interview 
Compared with before you received the InterStim® treatment, do you feel 
1. Much better   
2. Somewhat better 
3. No different 
4. Somewhat worse 
5. Much worse 
Compared with before you received the InterStim® treatment, what percentage 
improvement have you experienced?     (Scale of 0-100) 
 
If you had to do it over again, would you choose the InterStim® treatment? 
1. Yes 
2. No 
Are you satisfied with your InterStim® treatment? 
1. Yes 
2. No 
How many pads do you use on an average day? 
Have you sought any additional therapy for your urinary symptoms? 
1. Yes 
2. No 
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Table 3 Continued 
If “yes” to the above questions, then what treatments did you receive? 
1. Physical rehabilitation 
2. Medication 
3. Botulinum toxin injection 
4. Other 
 
 
Comparisons of UDI-6 and IIQ-7 scores, daily pad usage, and the number of 
recorded leak episodes per day before InterStim® placement and at time of final 
interview were made by paired Wilcoxon signed rank tests.  Response levels to 
individual questions on the UDI-6 and IIQ-7 surveys were dichotomized as “not at all” 
as equivalent to “no”, while “slightly”, ”moderately”, and “greatly” were recorded as 
“yes”.  
Proportions of subjects with various characteristics before treatment and at the 
final interview were compared by Chi-square or Fisher exact tests as appropriate.  Data 
were compared between satisfied and not satisfied subjects using one-way analysis of 
variance (ANOVA) for normally distributed variables, and by Kruskal-Wallis One-Way 
ANOVA on Ranks for non-normal variables.  Results were reported as percentage of 
subjects; means with 95% confidence intervals of the means for treatment comparisons 
of normally distributed variables; and medians with 95% confidence intervals of the 
median for non-normal data. 
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III.3  Results 
 
Forty-six subjects with refractory urinary urge incontinence and frequency and 
urgency underwent test stimulation for sacral neuromodulation between July 1, 2007 and 
August 30, 2010.  Forty-two of these subjects had successful test stimulation, proceeded 
to stage II IPG placement, and therefore met inclusion criteria.  The median age of these 
subjects was 67 (range 17-88) years at the time of IPG placement.  
Of the forty-two subjects eligible for telephone interview, 24 (52%) were 
contacted and provided responses.  One subject was contacted but unable to answer 
questions secondary to her advanced dementia.  One subject was contacted but declined 
the interview. Eight subjects were deceased, and 8 subjects did not respond to telephone 
calls or email requests (Figure 7).  The median time interval between IPG placement and 
follow-up interview was 51 months (range 39 to 59 months).    
Among the 24 subjects who were contacted and provided responses, 22 (92%) 
were treated for refractory urgency incontinence and 2 (8%) were treated for 
urgency/frequency syndrome.  Five of these 24 subjects had their IPG removed 
secondary to loss of efficacy.  Overall, nine (37.5%) of the 24 subjects who were 
contacted and provided responses were “satisfied” with InterStim® therapy, and 12 
(50%) stated that they would “do it all over again” (Figure 7). 
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Figure 7.  Subject flow chart
Subjects	eligible	for	
follow-up		
interview,	N=42	
Unable	to	be	
contacted	by	
telephone	or	email,		
N=8	
Deceased	prior	to	
interview,		
N=8	
Unable	to	answer	due	
to	demenBa,	N=1	
Declined	interview,	
N=1	
Completed	
interview,		
N=24	
"SaBsfied"		
N=9	
"Would	do	it	all	
over	again",		
N=9	
"DissaBsfied"		
N=15	
"Would	do	it	all	
over	again",		
N=3	
"Would	not	do	it	all	
over	again",		
N=12	
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Satisfied subjects reported a 50% median improvement [Likert-type scale] of 
their urinary symptoms compared to before receiving InterStim®.  Satisfied subjects 
were younger (Table 4) than dissatisfied subjects at the time of IPG placement (mean 51 
vs. 67; p = 0.01).  One subject, who was 17 years old was excluded from the age analysis 
because her age was lower than the average by more than three standard deviations.   
 
Table 4 Comparison of patients satisfied and dissatisfied at long-term follow-up with 
respect to preoperative characteristics and incontinence parameters 
Patient characteristic or 
incontinence parameter 
Dissatisfied 
(n = 14) 
Satisfied 
(n = 9) 
p 
Agea (years)  67 (62 - 72)  51 (37 – 65) 0.010 
Pad usagea (pads/day)     3.3 (1.9 – 4.7)   3.3  (0 – 2.5) 1.0 
24 hr pad weightb (g)  219 (113 – 379)  165 (34 – 554) 0.69 
Incontinence episodesb 
(episodes/day) 
    2.8 (1.0 – 7.3)   3.2        (0 – 7.0) 0.39 
 
a Data are mean (95% confidence interval) with p values derived from one-way ANOVA.   
b Data are median (95% confidence interval) with p values derived from Kruskal-Wallis 
One-Way ANOVA on Ranks 
 
At the time of follow-up interview, satisfied subjects demonstrated lower UDI-6 
scores (p = 0.0014, lower IIQ-7 scores (p = 0.033), greater symptom improvement (p = 
0.00022), and were wearing fewer pads per day (1.0 vs. 4.0, p = 0.0030) for protection 
compared to dissatisfied subjects (Table 5). Likewise, subjects who would “do it all over 
again” had both lower UDI-6 scores (p = 0.071), lower IIQ-7 scores (p = 0.030) and 
wore fewer pads  (1.3 vs. 3.8; p = 0.019) compared to those who would not “do it all 
over again.” 
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Table 5 Comparison of patients satisfied and dissatisfied at long-term follow-up with 
respect to postoperative (test phase) and long-term incontinence parameters and survey 
scores 
Patient characteristic or 
incontinence parameter 
Dissatisfied 
(n = 14) 
Satisfied 
(n = 9) 
p 
Postoperative follow-upa 
(months) 
 50 (46 – 54)  51 (46 – 56) 0.61 
Postoperative change in pad 
weight.b,c (percentage 
reduction) 
 80% (36 – 100)  93% (0 – 100) 0.22 
Postoperative change in dally 
pad usageb,d (pads/day 
reduction) 
 2.0 (0 – 4.0)  4.0 (0 – 6.0) 0.43 
Long-term reduction in daily 
pad usageb,e (pads/day 
reduction) 
 1.0 (-1.0 – 2.0)  -1.8 (-6.0 – 0) 0.017 
Long-term reduction in UDI-6 
scorea,e 
 14 (-11 – 29)  40 (5.5 – 65) 0.11 
Long-term reduction in IIQ-7 
scoreb,e 
 14 (-24 – 29)  43 (-38 – 86) 0.11 
 
a Data are mean (95% confidence interval) with p values derived from one-way 
ANOVA. 
b Data are median (95% confidence interval) with p values derived from Wilcoxon 
Signed-Rank Test for Difference in Medians 
c (24-hr pad weight before test stimulation - 24-hr pad weight during test 
stimulation)/(24-hr pad weight before test stimulation) 
d (Value before test stimulation) - (value during test stimulation) 
e (Value before test stimulation) - (value at long-term follow-up) 
    31 
Dissatisfied subjects were more likely to report urinary frequency (93% vs. 56%; 
p = 0.047), urinary urge incontinence (100% vs. 67%; p = 0.042), and stress urinary 
incontinence (87% vs. 33%; p = 0.021).  Dissatisfied subjects were significantly more 
likely than satisfied subjects to report that their symptoms affected their ability to 
perform housework (53% vs. 0%, p = 0.0095), exercise (p= 0.033), enjoy entertainment 
activities (p = 0.036), and travel by car or bus for a distance greater than 30 minutes 
from home (73% vs. 22%; p = 0.033).  Subjects who stated they would “do it all over 
again” were less likely to report that their symptoms affected their ability to perform 
housework, (8.3% vs. 58%; p = 0.027), exercise (33% vs. 75%; p = 0.041), and enjoy 
entertainment activities (42% vs. 83%; p = 0.089).  No difference between satisfied and 
dissatisfied subjects, respectively, was found regarding the median time interval in 
months since their last IPG evaluation (16 vs. 31; p = 0.46) or their last screening for 
urinary tract infection (12 vs.12; p = 0.67).  Dissatisfied patients were no more 
constipated then satisfied patients (38% vs. 57%; p = 0.64).   
When dissatisfied subjects were asked why they thought their InterStim® was 
not working, 2 stated that the InterStim® did not meet their expectations, and they were 
therefore not interested in seeking follow-up.  One subject thought that the IPG needed 
re-evaluation, but was unable to return for a follow-up visit due to lack of transportation.  
One subject could not provide an explanation for why they were dissatisfied, and one 
subject declined to provide an answer.  Finally, the percentage of dissatisfied subjects 
who reported they sought additional treatment did not significantly differ from satisfied 
subjects (14% vs. 22%; p = 1.0). 
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Satisfied subjects did not differ from dissatisfied subjects in their past medical 
history before InterStim® treatment nor at time of the follow-up (proportion with pelvic 
organ prolapse, menopause, hysterectomy, diabetes mellitus, hypertension, heart disease, 
lung disease, low back pain, GI disease, headaches, neurological diseases, blood clots, 
and/or kidney disease).  They also were similar in their obstetrical history (parity, 
vaginal deliveries, cesarean deliveries, largest baby, obstetrical laceration or trauma).  
Satisfied subjects did not differ from dissatisfied subjects with their objective voiding 
parameters (24-hour pad weight, daily pad usage, and number of leak episodes as 
documented on a 3-day bladder diary) recorded before the test stimulation phase or in 
post-void residual measured at that time (Table 4).  Satisfied subjects demonstrated less 
long-term reduction in daily pad usage.    
 
III.4  Discussion 
 
This study describes long-term satisfaction, symptom severity, and disease 
related quality of life in patients receiving sacral neuromodulation for the treatment of 
urinary urge incontinence, and urinary frequency and urgency.  We found that 37.5% of 
the 24 subjects who responded were still satisfied with sacral neuromodulation after a 
mean interval of 51 months, and 50% of those who responded affirmed they would “do 
it all over again.” This represents a dramatic decline in treatment satisfaction and 
willingness to repeat the procedure compared to the results reported by Foster et al (30) 
at 27 months in which 84% of respondents were satisfied and 80% would “do it all over 
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again”.   Our rates of satisfaction resemble those reported in a prospective follow-up 
study by Bosch and Growen (33).  They found that after 48 months, 18 (40%) of the 
patients were “cured,” and another 9 (20%) were considered “partially cured” at 48 
months.  These investigators defined treatment cure as a 90% reduction in pad use and/or 
incontinence episodes, while partial treatment cure was defined as a 50% to 90% 
reduction in pad use and/or incontinence episodes. 
Satisfied subjects in our study were on average 16 years younger at time of 
Interstim® IPG placement than dissatisfied subjects (Mean ± SEM: 51 ± 6.2 vs. 67 ± 2.3 
years; p=0.010).  The association between age and successful outcomes has been 
demonstrated before, in a 29 month prospective follow-up of 55 patients by Amundsen 
(34) and in which individuals younger than 55 years had a statistically significant greater 
cure rate (65% vs. 37 %).  This same study concluded that having three or more chronic 
conditions was associated with a lower cure rate in both younger and older individuals, 
and found that patients with neurologic conditions have lower cure rates.  Although we 
speculate that depression has a profound effect in patient’s perceived level of 
satisfaction, we did not believe we were capable of reporting accurate rates of this 
particular comorbidity without proper screening to capture undiagnosed cases within the 
cohort.    
We were not able to demonstrate any correlation between performance on 
objective test phase parameters and long-term satisfaction, unlike Foster et al. who found 
a significant association with improvement (84%) on 24-hour pad test weight during test 
stimulation and patient satisfaction and desire to “do it all over again” after 27 months.  
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Our lack of finding an association is consistent with results previously reported (32, 34-
36).   
We do not believe that the lack of association between improvement 
demonstrated on objective voiding parameters (24-hour pad weight, 3 day bladder diary 
and pad usage) during test stimulation invalidates their use for screening eligible patients 
for IPG placement, as we were underpowered to detect these associations.  Clearly, 
patients need to demonstrate some level of improvement prior to undergoing 
implantation of a permanent and expensive treatment modality.  However, other factors 
must be incorporated in calculating estimated long-term efficacy.  The ability to convey 
accurate and realistic expectations will be paramount to patient satisfaction.  Even with 
less then optimal improvement patients can still experience satisfaction if appropriate 
expectations are established.  Perhaps, a long-term efficacy/satisfaction prediction model 
may be created similar to the one constructed to estimate the risk of de novo stress 
urinary incontinence after vaginal pelvic organ prolapse surgery (37).  
We were unable to demonstrate associations between subject satisfaction and 
constipation, time interval since last IPG evaluation, and time interval since last check 
for a urinary tract infection. However, differences were present, and these differences 
may have been significant with higher power.  Associations amongst these variables 
would imply that subject satisfaction with sacral neuromodulation depends on patients 
taking ownership of their disease and being pro-active in managing their health.  This 
includes pro-actively managing their bowel function, and being self-motivated to 
seeking evaluation for possible urinary tract infections and seeking evaluation of their 
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IPG.  The 2 dissatisfied subjects who reported that their InterStim® “did not meet their 
expectations, and were therefore not interested in seeking follow-up” did not return for 
IPG re-evaluation after the stage II procedure.  It is reasonable to argue that successful 
outcomes, and therefore patient satisfaction with sacral neuromodulation, depends on 
how well the patient cares for his or herself and complies with scheduled maintenance 
for their IPG.  
The 37.5% satisfaction rate further illustrates the challenge in treating urinary 
urge incontinence, frequency and urgency.   Despite this relatively low level of reported 
subject satisfaction at 53 months, it still represents an improvement over anticholinergic 
therapy when one considers the high rates of discontinuation of these drugs due to 
perceived ineffectiveness and side effects (38).     
Strengths of the study include the prospective design and use of validated 
questionnaires.  Several weaknesses need to be addressed.  First of all, there was a 
limited cohort size (41) and a limited number of subjects (24) providing responses for 
the long-term follow-up interview, which makes it difficult to draw conclusions.  
Second, we did not distinguish patients who may have had mixed urinary incontinence 
in our analysis, as this may have resulted in a difference in satisfaction.  Future studies 
should include a cohort sufficiently large to account for the large number of patients lost 
to follow-up or deceased.  Because of the telephone interview format, we were unable to 
report performance and objective parameters such as the 3-day bladder diary and 24-
hour pad weight.  This prevented us from describing associations between reported 
subject satisfaction and these parameters.  Furthermore, we were unable to assess long-
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term satisfaction of sacral neuromodulation for treating non-obstructive urinary retention 
because we had no patients that met criteria.  Future studies should include the ability to 
accurately account for depression. 
 In conclusion, after a mean follow-up interval of 51 months, 37.5% of subjects 
still reported being satisfied with sacral neuromodulation for the treatment of urinary 
urge incontinence and urinary urgency and frequency, while 50% reported they would 
“do it all over again.”  Except for younger age, statistical analysis of multiple factors did 
not reveal predictive variables for patient satisfaction or willingness to repeat the 
therapy.  Given the small cohort study available for telephone interview (24 subjects) 
further studies with a larger cohort size are needed to identify predictive variables for 
clinical success, correlate duration of disease with clinical efficacy and patient 
satisfaction, and to determine differences in patient follow-up and reprogramming 
between satisfied and non-satisfied patients. 
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CHAPTER IV 
FUTURE DIRECTIONS AND CONCLUSIONS 
 
IV.1 Future Directions 
 
The pelvic floor muscles—pubococcygeous-puborectalis complex-- interact with 
connective tissue to provide the primary support for the pelvic organs by countering 
intra-abdominal and gravitational forces applied to the vagina through constant muscle 
tone (14, 39).  Pelvic floor weakness secondary to neuropathic injury or mechanical 
muscular damage results in the endopelvic fascia becoming the primary mechanism of 
support, eventually leading to loss of normal anatomic position through breaks and 
attenuation of this support.   
Clinical research and imaging studies of the pelvic floor have demonstrated the 
effects of childbirth on pelvic floor musculature (39).  The levator hiatus, which is 
defined by the puborectalis and pubococcygeus muscles and pubic bone, is considered to 
be the largest hernia portal in the human body (40).  It has been studied in humans using 
both MRI (41) and ultrasound technology (40, 42).  In human studies using 3D and 4D 
ultrasound imaging, hiatal dimensions have been observed to be larger with age (43), 
parity (44) and vaginal childbirth (45).  In addition, larger hiatal dimensions have been 
observed in women with greater pelvic organ descent (40).  
Using MRI, Handa et al assessed human pelvic anatomy and pelvic floor 
disorders 6-12 months following delivery (41).   The investigators designated the 
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pubococcygeal line to be the normal location of the pelvic floor and defined the genital 
hiatus as the distance from the inferior posterior aspect of the symphysis to the posterior 
rectal wall at the anorectal junction in the most cranial mid-sagital image that included 
the symphysis.  They did not observe differences in soft tissue dimensions between 
women with and without pelvic floor disorders, including anterior vaginal prolapse.  
Because the squirrel monkey has established its self as an experimental model 
that is useful for studying pelvic organ prolapse in humans (10, 11), future studies 
describing the soft-tissue anatomy of the genital hiatus and pelvic floor in this species 
should be pursued.  Once this anatomy has been described, then experiments seeking to 
determine associations between soft-tissue dimensions of the genital hiatus and pelvic 
floor and the development of pelvic organ prolapse in squirrel monkeys can and should 
be performed.   As described earlier, the boney pelvic outlet diameters in squirrel 
monkeys were assessed for associations with pelvic organ prolapse (46).   If associations 
between hiatal dimensions and age, parity, mode of offspring delivery, and prolapse are 
found to be similar between squirrel monkeys and humans, hypotheses built on 
intervention for preventing pelvic organ prolapse can be performed in monkeys that 
cannot be performed in humans.   Future studies should seek to determine the association 
of prolapse, age, parity, and mode of delivery on hiatal dimensions in squirrel monkeys.  
This would further validate the squirrel monkey as an animal model, and therefore 
enable testing hypotheses that involve interventions. 
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IV.2  Conclusions
Human pelvic floor disorders have and will continue to pose a significant 
medical challenge to our health system.  Research aimed at further determining risk 
factors for the development of pelvic organ prolapse and urinary incontinence will not 
only enhance our understanding the disease, but more importantly help us formulate 
hypothesis directed at interventions that may prevent their onset and progression.  
Animal models such as the squirrel monkey will have influential roles in the 
experimental design of future studies seeking to determine the effectiveness of 
hypothetical interventions.   Innovative therapies such as sacral neuromodulation 
(InterStim®, Medtronic, Inc., Minneapolis, MN) will require vigorous studies to 
determine their effectiveness in treating disease and therefore its usefulness to our health 
system.   It will be imperative that future research design incorporates a combination of 
domains including subjective assessment of symptoms, objective quantification of 
symptoms, clinician’s observations and examination, improvements in quality of life, 
and any socioeconomic measures, in order to draw meaningful conclusions to the value 
of that particular treatment.  
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